SynthesisInternational journal of colorectal disease2025
Outcomes of the management of synchronous rectal and prostate cancer: a systematic review.
Synthesis in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal management of synchronous rectal cancer (RC) and prostate cancer (PC) remains unclear. This systematic review evaluates treatment strategies and reports postoperative, oncological, and quality-of-life outcomes in patients treated with curative intent.
methodsFollowing PRISMA guidelines, this systematic review was registered in PROSPERO (CRD42024598049). A search of Ovid MEDLINE, Embase, CENTRAL, and CDSR (inception to February 2025) identified randomised controlled trials and observational studies on synchronous RC and PC. Synchronous disease was defined as diagnosis or treatment initiation within 12 months. Patients with incurable RC were excluded. Treatment strategies and surgical approaches were analysed, with postoperative, oncological, and survival outcomes assessed.
resultsEight retrospective studies (124 patients) were included. Common treatments included pelvic chemoradiotherapy (CRT) followed by surgery (29%), prostate booster radiotherapy with CRT (24.2%), prostate brachytherapy (8%), and no prostate-directed treatment (11.3%). Surgical approaches included total mesorectal excision (TME) (74.4%), TME with prostatectomy (10.8%), and en-bloc pelvic exenteration (8%). Primary anastomosis was achieved in 61.8%, with 70% requiring a diverting stoma. Anastomotic leaks occurred in 10.8%, and severe complications (grades 3b-5) affected 15.4%, with fewer in robotic-assisted surgery (8.3%). R0 resection was achieved in 92.8%, with no difference between robotic and non-robotic groups. Local recurrence and distant metastasis occurred in 5.9% and 27%, respectively.
conclusionThere is no consistent approach for managing synchronous RC and PC. High-dose prostate radiotherapy may not improve survival and may increase postoperative complications. Robotic-assisted resections may reduce major complications without compromising oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.